Lithuanian inventions and science

Curated content — every claim carries its source. The two sections above are pulled from Eurostat and recomputed on every visit; the claims below are read off documents, so each one names the body that made it and links the page it is printed on.

Research and development spending

Gross domestic expenditure on research and development as a share of GDP (Eurostat), Lithuania beside the EU27 average, year by year.

Lithuania
1.04 %
2024
20 of 27 in the EU · EU average 2.24 % · our calculation from Eurostat, 2024
EU average
2.24 %
2024
01.142.281995200020052010201520202024LithuaniaEU average
Year Lithuania EU average
2024 1.04 % 2.24 %
2023 1.04 % 2.26 %
2022 1.06 % 2.22 %
2021 1.10 % 2.24 %
2020 1.12 % 2.28 %
2019 0.99 % 2.21 %
2018 0.93 % 2.17 %
2017 0.90 % 2.14 %
2016 0.84 % 2.10 %
2015 1.04 % 2.10 %
2014 1.03 % 2.09 %
2013 0.95 % 2.08 %
2012 0.90 % 2.06 %
2011 0.91 % 2.00 %
2010 0.79 % 1.96 %
2009 0.83 % 1.96 %
2008 0.79 % 1.87 %
2007 0.80 % 1.79 %
2006 0.79 % 1.80 %
2005 0.75 % 1.78 %
2004 0.75 % 1.79 %
2003 0.66 % 1.82 %
2002 0.66 % 1.83 %
2001 0.67 % 1.82 %
2000 0.58 % 1.81 %
1999 0.50 % 1.78 %
1998 0.54 % 1.73 %
1997 0.53 % 1.72 %
1996 0.49 % 1.72 %
1995 0.43 % 1.73 %

Source: Eurostat

Patent applications

Applications to the European Patent Office per million inhabitants, counted by the inventor's country of residence (Eurostat).

No rank is shown here, and none should be. Lithuania files 70–130 EPO applications in a year, so one research group's filings move the country several places up the EU table and back down the year after: a rank off that base would report noise as news. The whole run of years is shown instead.

Eurostat flags the latest year (2025) as provisional, so that figure may still be revised.

02346201120122014201620182020202220242025
Year Applications per million inhabitants
2025 32.17
2024 26.31
2023 45.97
2022 29.67
2021 25.29
2020 19.22
2019 12.10
2018 13.48
2017 9.86
2016 8.69
2015 14.09
2014 8.52
2013 7.43
2012 6.03
2011 5.29

Source: Eurostat

Lasers

CRISPR-Cas9